Lorus Therapeutics Files Registration Statement With SEC

TORONTO, ONTARIO, Apr 06 (MARKET WIRE) --
Lorus Therapeutics Inc. (TSX: LOR) ("Lorus"), a biopharmaceutical company
specializing in the research and development of pharmaceutical products
and technologies for the management of cancer, announced today that it
filed a Registration Statement on Form F-1 (the "Registration Statement")
with the United States Securities and Exchange Commission (the "SEC") for
an offering of up to US$17,500,000 of units in the United States. Global
Hunter Securities, LLC has been engaged to act as the placement agent in
connection with the offering.

This registration will allow Lorus to offer and issue units, each unit
consisting of one common share and one half of a warrant (a "Warrant") to
purchase common shares (collectively referred to as the "Securities").
Each whole Warrant will permit the holder to purchase one common share,
at an initial exercise price of 125% of the unit offering price (which
will be determined at the time of the offering), and subsequently at a
premium to the unit offering price which rises 5% on each anniversary of
the closing date, to a maximum exercise price of 145% of the unit
offering price on the fourth anniversary of the closing. Lorus may also
require the exercise of the Warrants if the closing price of the common
shares on the principal market upon which they are traded equals or
exceeds 225% of the unit offering price for five consecutive trading days.

Lorus intends to use the net proceeds from the sale of any Securities to
fund its product development programs, including further development of
the LOR-2040 clinical program, Phase I clinical development for LOR-253
as well as other research programs, and to fund working capital and for
other general corporate purposes.

The Registration Statement relating to the Securities has been filed with
the SEC but has not yet become effective. The details of the offering
(including the terms of the Securities) are subject to change based on
market conditions at the time the Registration Statement becomes
effective. The offering is subject to regulatory approval, including the
approval of the Toronto Stock Exchange.

The Securities may not be sold, nor may offers to buy be accepted, before
the Registration Statement becomes effective. This news release shall not
constitute an offer to sell or the solicitation of an offer to buy the
Securities, nor shall there be any sale of the Securities in any
jurisdiction in which such offer, solicitation or sale would be unlawful
prior to registration or qualification under the securities laws of such
jurisdiction.

A copy of the prospectus included in the Registration Statement can be
obtained upon request by contacting Investor Relations at the contact
information below.

About Lorus

Lorus is a biopharmaceutical company focused on the discovery, research
and development of novel therapeutics in cancer. Lorus' goal is to
capitalize on its research, preclinical, clinical and regulatory
expertise by developing new drug candidates that can be used, either
alone, or in combination with other drugs, to successfully manage cancer.
Through its own discovery efforts and an acquisition and in-licensing
program, Lorus is building a portfolio of promising anticancer drugs. The
common shares of Lorus Therapeutics Inc. are listed for trading on the
Toronto Stock Exchange under the symbol LOR.

Forward Looking Statements

Certain statements contained in this press release constitute
forward-looking statements or information (collectively "forward-looking
statements") within the meaning of the "safe harbour" provisions of
applicable securities legislation. Forward-looking statements are
typically identified by words such as "anticipate", "continue",
"estimate", "expect", "forecast", "may", "will", "project", "could",
"plan", "intend", "should", "believe", "outlook", "potential", "target"
and similar words suggesting future events or future performance. In
particular, this press release contains, without limitation,
forward-looking statements pertaining to:

- a possible sale of Securities by Lorus in the United States pursuant to a
Registration Statement;
- the maximum amount of the offering;
- the terms of the Securities;
- the use of the net proceeds received from any sale of Securities pursuant
to the Registration Statement;
- general economic conditions;
- Lorus' future business prospects and opportunities, including, without
limitation, Lorus' financial situation;
- investor demand;
- the outcome of the proposed offering; and
- Lorus' inability or failure to obtain adequate financing on a timely
basis.

With respect to forward-looking statements contained in this press
release, we have made assumptions regarding various matters, including
the matters identified in the Registration Statement. Although we believe
that the expectations reflected in the forward-looking statements
contained in this press release, and the assumptions on which such
forward-looking statements are made, are reasonable, we cannot assure you
that such expectations will prove to be correct.

Readers are cautioned not to place undue reliance on forward-looking
statements included in this press release, as there can be no assurance
that the plans, intentions or expectations upon which the forward-looking
statements are based will occur. By their nature, forward-looking
statements involve numerous assumptions, known and unknown risks and
uncertainties that contribute to the possibility that the predictions,
forecasts, projections and other forward-looking statements will not
occur, which may cause our actual performance and financial results in
future periods to differ materially from any estimates or projections of
future performance or results expressed or implied by such forward
looking statements. These risks and uncertainties include those
identified in the Registration Statement.

The forward-looking statements contained in this press release speak only
as of the date of this press release. Except as expressly required by
applicable securities laws, we do not undertake any obligation to
publicly update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise. The
forward-looking statements contained in this press release are expressly
qualified by this cautionary statement.

Contacts:
Lorus Therapeutics Inc.
Dr. Saeid Babaei
416-798-1200 ext. 490
ir@lorusthera.com

Copyright 2010, Market Wire, All rights reserved.

-0-